COMMUNIQUÉS West-GlobeNewswire

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

12/09/2024 - 14:00

VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and [...]

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

12/09/2024 - 14:00

WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive [...]

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

12/09/2024 - 14:00

CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]

Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting

12/09/2024 - 14:00

NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented [...]

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

12/09/2024 - 14:00

Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantation Histological data confirmation of healthy beta, alpha and delta [...]

CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim

12/09/2024 - 14:00

New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction MINNEAPOLIS, Sept. 12, 2024 (GLOBE NEWSWIRE [...]

PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV

12/09/2024 - 14:00

MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, was recently featured in the Sight & [...]

Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management

12/09/2024 - 14:00

Review Published in the Prestigious Journal Cardiorenal Medicine Oak Ridge, TN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today [...]

Acasti to Present at the Life Sciences Investor Forum

12/09/2024 - 14:00

PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that [...]

PetMed Express, Inc. Announces Appointment of Robyn D’Elia as Chief Financial Officer

12/09/2024 - 14:00

D’Elia Brings More than 25 Years of Strategic Finance and Retail Leadership Experience to PetMeds DELRAY BEACH, Fla., Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , dba PetMeds and parent company of PetCareRx [...]

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

12/09/2024 - 14:00

LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Elevar Therapeutics Reports Advances in HCC and Other Oncology Clinical Programs for Rivoceranib Plus Camrelizumab at the European Society for Medical Oncology Congress 2024

12/09/2024 - 14:00

FORT LEE, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the presentation of three posters at the European Society for Medical Oncology [...]

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

12/09/2024 - 14:00

On track to announce topline results from ORIGIN 3 trial in Q2 2025 Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024 BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE [...]

Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act

12/09/2024 - 14:00

Scorpius Poised to Support Expanded U.S. Government-Backed Project Pipeline as U.S. Drugmakers Seek to Shift to Domestic Suppliers Amid Industry-Changing Legislation DURHAM, N.C., Sept. 12, 2024 (GLOBE NEWSWIRE) -- [...]

Biogen Board Appoints Two New Independent Directors

12/09/2024 - 13:30

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc [...]

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12/09/2024 - 13:30

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at [...]

Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories

12/09/2024 - 13:30

CINCINNATI, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, and Swedish Orphan Biovitrum [...]

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

12/09/2024 - 13:30

SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to [...]

VitalCaring’s AI-driven Cognitive Care Pilot Shows Promising Results

12/09/2024 - 13:26

National leader in home health and hospice care to extend AI-enabled speech, language, and cognitive therapy initiative across its network DALLAS and LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VitalCaring , a [...]